Adaptimmune Therapeutics plc (ADAP)

Market Cap	71.19M
Revenue (ttm)	179.64M
Net Income (ttm)	-69.90M
Shares Out	265.05M
EPS (ttm)	-0.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	317,731
Open	0.2688
Previous Close	0.2743
Day's Range	0.2620 - 0.2749
52-Week Range	0.1951 - 1.4800
Beta	2.19
Analysts	Buy
Price Target	1.35 (+402.61%)
Earnings Date	Aug 11, 2025

About ADAP

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 6, 2015
• Employees: 506
• Stock Exchange: NASDAQ
• Ticker Symbol: ADAP
• Website: https://www.adaptimmune.com

Financial Performance

In 2024, Adaptimmune Therapeutics's revenue was $178.03 million, an increase of 195.34% compared to the previous year's $60.28 million. Losses were -$70.81 million, -37.81% less than in 2023.

Analyst Summary

According to 6 analysts, the average rating for ADAP stock is "Buy." The 12-month stock price target is $1.35, which is an increase of 402.61% from the latest price.

Price Target

$1.35

(402.61% upside)

Analyst Consensus: Buy